What is Countable Labs?
Countable Labs operates as a specialized biotechnology enterprise dedicated to the advancement of precision genomics. By engineering innovative DNA quantification technologies, the company addresses critical bottlenecks in molecular measurement, offering solutions that enhance the sensitivity and accessibility of genomic data. Their core technology reimagines standard PCR-based methodologies, effectively simplifying complex laboratory workflows for researchers and healthcare professionals alike.
The company's market position is defined by its commitment to actionable biological insights. By facilitating more reliable data acquisition, Countable Labs supports a diverse array of high-impact applications, including clinical diagnostics, biomarker discovery, and the burgeoning field of gene therapy. Their platform is designed to bridge the gap between raw molecular data and clinical decision-making, providing a robust foundation for the next generation of life science research.
How much funding has Countable Labs raised?
Countable Labs has raised a total of $26M across 1 funding round:
Unspecified
$26M
Unspecified (2026): $26M with participation from Primer Ventures, ARCH Venture Partners, and F-Prime Capital Partners
Key Investors in Countable Labs
Primer Ventures
Primer Ventures is an investment firm dedicated to partnering with visionary entrepreneurs to transform healthcare through innovation, focusing on early-stage investments in life science tools and therapeutics.
ARCH Venture Partners
ARCH Venture Partners is a leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups with scientists and entrepreneurs.
F-Prime Capital Partners
F-Prime Capital provides a team of investors, engineers, doctors, and scientists dedicated to investing in health care and technology, leveraging deep domain expertise to support portfolio growth.
What's next for Countable Labs?
With this major enterprise-level funding, Countable Labs is well-positioned to scale its operations and broaden the reach of its genomic analysis platform. The strategic roadmap likely involves intensifying R&D efforts to further refine its DNA quantification tools while simultaneously building out the commercial infrastructure necessary for widespread adoption in clinical and research settings.
Looking ahead, the company is expected to leverage this capital to forge deeper partnerships within the life sciences ecosystem, particularly in areas where high-precision diagnostics are paramount. By focusing on the integration of its technology into existing diagnostic pipelines, Countable Labs aims to solidify its role as an essential provider of genomic infrastructure, ultimately driving the shift toward more personalized and data-driven healthcare outcomes.
